Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Overexpression of the HER2 gene accounts for 20% to 30% of breast cancer. Although
trastuzumab combined with chemotherapy has become the basic treatment for patients with
HER2-positive advanced breast cancer, For patients who have progressed or relapsed after
trastuzumab treatment, There are still many issues to explore on the choice of program of
retargeted therapy. In HER2-positive advanced breast cancer, the results of Phase I and Phase
I/II trials of pyrotinib or pyrotinib combined with capecitabine show that the anti-tumor
effect is rapid, efficient and sustainable, and the patient is safe and well tolerated.
Capecitabine is an oral cytotoxic drug that has high selectivity and specificity against
tumors. Many patients need to adjust the dose due to adverse reactions, especially for
patients after multi-line treatment. Previous studies have shown that sustained low-dose
capecitabine reduces the adverse effects of the drug while ensuring efficacy. Based on the
above, this study is to conduct a single-center, one-arm phase II clinical trial to explore
the efficacy and safety of pyrotinib and capecitabine in the treatment of HER2-positive
advanced breast cancer.